Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 11/20 | 0.62 |
| ▸ | NPBWR1 | P48145 | 8/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | THRA | P10827 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6219582 | 0.94 | NPBWR1 (0.59) | THRBNPBWR1MCHR1NPSR1LMNA | |
| SCHEMBL25827400 | 0.90 | THRB (0.66) | THRBNPBWR1THRA | |
| SCHEMBL24781755 | 0.85 | THRB (0.63) | THRBTHRA | |
| SCHEMBL6213829 | 0.82 | THRB (0.64) | THRBTHRA | |
| SCHEMBL9503278 | 0.82 | THRB (0.59) | THRBTHRA | |
| SCHEMBL9501104 | 0.81 | THRB (0.60) | THRBTHRA | |
| SCHEMBL9502425 | 0.81 | THRB (0.82) | THRBTHRA | |
| SCHEMBL6214365 | 0.81 | THRB (0.55) | THRBTHRA | |
| SCHEMBL6212526 | 0.81 | THRB (0.62) | THRBTHRA | |
| SCHEMBL6216674 | 0.80 | THRB (0.66) | THRBNPBWR1MCHR1THRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6930107-B2 | 6-azauracil derivatives as thyroid receptor ligands | PFIZER INC. (US) | 2005-08-16 | — | — | US | disclosed |
| EP-1088819-B1 | 6-azauracil derivatives as thyroid receptor ligands | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6787652-B1 | LOWERING LIPIDS AND SERUM CHOLESTEROL WITHOUT GENERATING ADVERSE CARDIAC EFFECTS; 4,5-DIHYDRO-3,5-DIOXO-1,2,4-TRIAZINE DERIVATIVES | PFIZER, INC. | 2004-09-07 | — | — | US | disclosed |
| US-20040157844-A1 | 6-azauracil derivatives as thyroid receptor ligands | DOW ROBERT L (US) | 2004-08-12 | — | — | US | disclosed |
| EP-1088819-A2 | 6-azauracil derivatives as thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157844-A1 | 6-azauracil derivatives as thyroid receptor ligands | TSHR, THRA, THRB | THRB 3/4885NPBWR1 381/4885MCHR1 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.